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Abstract 
Background: Aluminum phosphide (AlP) is a very effective indoor and outdoor pesticide. We investigated the effects 
of N‑acetyl cysteine (NAC) on the survival time, hemodynamics, and cardiac biochemical parameters at various time 
intervals in some cases of AlP poisoning.
Methods: This research was a case–control study to evaluate 63 AlP poisoned patients during 2010–2012. Patients 
with cardiovascular complications of AlP to be treated with intravenous NAC plus conventional treatment were 
considered as the case group and compared with patients who did not receive NAC. NAC infusion was administered 
to the case group at 300 mg/kg for 20 h. The data gathered included age, sex, heart rate, Systolic blood pressure (SBP), 
creatine phosphokinase (CPK), creatine kinase MB (CK‑MB), and ECG at the admission time and 12, 18, and 24 h after 
admission. Analysis of repeated measures was performed to check the variability of parameters over time.
Results: The mean ages in the case and control groups were 26.65 ± 1.06 (19–37 years) and 28.39 ± 1.11 (18–
37 years), respectively (P = 0.266). Most of the patients were female (56.5%). CK‑MB means were significantly different 
between the two groups, but no differences between the other variables were observed. Also, CK‑MB, CPK, heart 
rate, and systolic blood pressure means became significantly different over time (0, 12, 18, and 24 h) in both groups 
(P < 0.001). NAC prevented sharp heart rate fluctuations in AlP patients in the case group. Regarding the outcomes, 17 
patients died (10 patients in the control and 7 patients in the case groups). No side‑effects of NAC were observed.
Conclusion: Our patients could be managed by the positive role of NAC as the biochemical index of cardiotoxicity 
was found to elevate in both the case and control groups. Therefore, for the management protocol optimization, NAC 
evaluation should be done in further cases.
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Background
Aluminum phosphide (AlP) is a very effective indoor and 
outdoor pesticide used in some developing countries 
(Mehrpour and Singh 2010). In Iran, it is also called rice 
tablet, which is mainly used to protect rice and grains 
during storage. The main mechanisms of toxicity are 
inhibition of cytochrome oxidase c, as well as oxidative 
stress (Mehrpour et  al. 2009, 2014a). After contacting 
with moisture, AlP releases phosphine gas, which is a 
lethal poison (Mehrpour et al. 2012). The mortality rates 
caused by AlP poisoning have been demonstrated as high 
as 70–100% in various studies (Mehrpour et  al. 2012). 
The main cause of death is a refractory cardiogenic shock 
(Mehrpour et al. 2011, 2014b). Moreover, other contrib-
uting factors include severe hypotension and severe and 
refractory metabolic acidosis. Since the cardiovascular 
system is the main target of this poison, various electro-
cardiographic changes including dysrhythmias may occur 
by this fatal poisoning.
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NAC is an important antioxidant and a cytoprotective 
agent that replenishes intracellular glutathione. In animal 
studies, NAC has been shown to have a protective role 
against cardiovascular complications by protecting heart 
cells from the oxidative stress induced by phosphine 
(Shakeri and Mehrpour 2014). Therefore, we investi-
gated the effects of NAC on hemodynamics and cardiac 
biochemical parameters of AlP poisoning cases at vari-
ous time intervals as well as during the survival time and 
compared them with those of the control group.
Methods
This research was a case–control study conducted in 
Baharloo Teaching Hospital, a referral poisoning center 
in Tehran, Iran during 2010–2012 (Mehrpour and Abdol-
lahi 2012). AlP-poisoned patients were included in the 
study during the study period. The patients without any 
symptoms and signs for 12 h and unreliable history and 
those who died during the first 24 h were excluded from 
the study. The treatment group (case group) received 
intravenous NAC plus a conventional treatment. The 
control group consisted of the patients undergoing only 
conventional treatment for AlP poisoning. The conven-
tional treatment as our local guideline was administered 
to both groups included lavage with KMnO4, magnesium 
sulphate (1 g initially followed by 1 g every 6 h), 10% cal-
cium gluconate (1 g initially followed by 1 g every 6 h), 
hydrocortisone (200  mg initially followed by 200  mg 
every 6  h), vitamin C (1000  mg every 12  h via slow 
intravenous infusion), vitamin E (400 units intramuscu-
larly) NaHCO3  administration for treatment of acidosis 
(Mehrpour et  al. 2008; Oghabian and Mehrpour 2016). 
NAC infusion was administered to the mentioned group 
at 300 mg/kg for 20 h. The outcomes were considered for 
changes in the hemodynamic and cardiac biochemical 
parameters at the survival time. The patients were also 
evaluated based on NAC side-effects.
The data gathered included age, sex, heart rate, blood 
pressure, creatine phosphokinase (CPK), creatine kinase-
MB fraction (CK-MB), and ECG at the time of admission 
and 12, 18, and, 24 h after admission.
The patients were transferred to the Intensive Care 
Unit (ICU) in case they had an arterial pH less than 
7.34 besides cardiovascular symptoms. The data were 
recorded on a checklist. IBM SPSS 22 was used for 
the statistical analysis. The data were presented as 
mean  ±  SE. Chi Square or Fisher’s exact test was used 
to compare the two groups. Also, analysis of repeated 
measures was performed to compare the means between 
and among the groups at different evaluation times. Fig-
ures show the estimated marginal means in each time 
for both groups. The Estimated Marginal Means are the 
mean response for each factor, adjusted for any other 
variables in the model. It means that the Estimated Mar-
ginal Means adjust for the covariate by reporting the 
means of response variable for each level of the factor at 
the mean value of the covariate. A P value less than 0.05 
was considered as significant. An informed consent was 
obtained from alert patients or their first-degree families 
or relatives. The study protocol was approved by the ethi-
cal committee of Tehran University of Medical Sciences, 
Tehran, Iran (No. 345).
Results
63 Patients with AlP poisoning (caused by oral consump-
tion) were admitted during the study period. The data of 
46 patients (23 patients in each group) were analyzed in 
the study since 17 patients died and were excluded from 
the study.
The mean ages in the case and control groups were 
26.65 ± 1.06 (19–37 years) and 28.39 ± 1.11 years (18–
37  years), respectively (P  =  0.26). Most of the patients 
were female (56.5%) (69.6 and 43.5% in the case and con-
trol groups, respectively).
The analysis of variance and repeated measures showed 
that CK-MB means were significantly different between 
the two groups. However, no significant differences were 
seen between the groups based on the other variables. 
Also, CK-MB, CPK, heart rate, and systolic blood pres-
sure means were significantly different over time (0, 12, 
18, and 24 h) in the case and control groups. The results 
revealed that CK-MB means were significantly different 
after 12, 18, and 24  h of admission in comparison with 
the admission times in both groups (P  <  0.001). Also, 
there were significant differences between CPK means 
after 18 and 24 h of admission compared to the admission 
times in both groups (P < 0.001). Heart rate means were 
different 18 h after admission compared to the admission 
time in the control group (P < 0.001). There were signifi-
cant differences between systolic blood pressure means 
after admission times compared with the admission time 
in NAC group (P < 0.001). Different means were obtained 
between 12 and 18  h after admission and at the admis-
sion time in the control group (P < 0.001) (Table 1).
At the time of admission, sinus tachycardia, sinus 
bradycardia, PVC, QRS widening, ST-elevation MI were 
observed in 13.0, 8.7, 4.3, 8.7, and 8.7% in the control 
group respectively. In the case group, sinus tachycardia, 
sinus bradycardia, PVC, widening of QRS, and ST-ele-
vation MI were discovered in 17.4, 4.3, 4.3, 8.7, and 4.3% 
of the patients, respectively. 12 h after admission, Sinus 
tachycardia, sinus bradycardia, PVC, widening of QRS, 
ST-elevation MI, and AF were seen in 17.4, 4.3, 4.3, 8.7, 
8.7, and 4.3% of the patients in the case group, respec-
tively. After 18  h, sinus bradycardia, PAC, widening of 
QRS, ST-elevation MI, VT, and VF were observed in 8.7, 
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4.3, 4.3, 8.7, 13.0, and 4.3% of the case group, respec-
tively, while 2 patients died. The evaluations after 24 h of 
admission indicated that sinus tachycardia, sinus brady-
cardia, PAC, widening of QRS, ST-elevation MI, AF, and 
VT had occurred in 4.3, 6.3, 4.3, 4.3, 13.0, 4.3, and 4.3% 
of patients in the case group, respectively. There were no 
significant differences between the two groups (P value 
>0.05) (Table 2).
A sudden drop in the heart rates of patients in the con-
trol group was observed after 12 and 18 h of admission 
and then they increased (Fig.  1c). However, using NAC 
in the case group could prevent sharp fluctuations in the 
heart rates in AlP patients (Fig. 1e). Moreover, a sudden 
decrease in the systolic blood pressures of the patients 
who had received NAC and those of the control group 
in receiving it in a similar way was observed, while the 
systolic blood pressures rose sharply to their normal val-
ues in the patients who had got NAC for their treatments 
between 18 and 24 h after admission (Fig. 1d). Regarding 
the outcomes, 17 patients died [10 patients in the control 
and 7 patients in the treatment (case) groups]. No side-
effects of NAC were observed.
Discussion
The generation of superoxide radicals and cellular perox-
ides is resulted from the inhibitory effects of phosphine 
on mitochondrial cytochrome-C oxidase. Lipid peroxida-
tion and other oxidant mechanisms subsequently lead to 
cellular injury. It has been reported that the toxins gen-
erated by AlP ingestion leads to a profound circulatory 
collapse, as the major lethal consequence that directly 
affects cardiac myocytes and causes adrenal gland 
Table 1 Characteristics of variables in different times in two groups
CK-MB creatine kinase-MB fraction, CPK creatine phosphokinase, HR heart rate, SBP systolic blood pressure case group received NAC beside conventional therapy
* Significantly different with admission time in each group
Variables Group Admission time 12 h after admission 18 h after admission 24 h after admission
Mean (SE) Mean (SE) Mean (SE) Mean (SE)
CK‑MB Control 20.45 (1.1) 40.54 (0.9)* 51.45 (1.7)* 70.09 (2.6)*
Case (NAC) 23.69 (1.8) 40.53 (1.9)* 52.30 (2.3)* 68.07 (2.2)*
P value 0.54 0.76 0.11 0.21
CPK Control 320.90 (38.6) 344.90 (23.5) 726.36 (44.1)* 1182.81 (114.9)*
Case (NAC) 358.15 (48.8) 367.69 (30.2) 726.69 (68.2)* 1004.69 (172.5)*
P value 0.82 0.51 0.34 0.31
HR Control 80.36 (3.9) 73.45 (4.7) 69.63 (5.1)* 75.81 (4.0)
Case (NAC) 82.76 (3.1) 77.69 (6.1) 78.46 (4.6) 77.76 (3.7)
P value 0.88 0.75 0.45 0.56
SBP Control 106.63 (2.4) 98.81 (2.5)* 93.18 (1.2)* 96.54 (1.2)
Case (NAC) 100.15 (3.9) 93.30 (1.5)* 94.38 (4.1)* 102.61 (2.7)*
P value 0.23 0.94 0.55 0.32
Table 2 Distribution of ECG changes in different times
NAD no abnormality detected
ECG changes Admission time 12 h 18 h 24 h
Case (%) Control (%) Case (%) Control (%) Case (%) Control (%) Case (%) Control (%)
No evidence 56.5 60.9 39.1 47.8 34.8 43.5 26.1 30.4
Sinus tachycardia 13.0 17.4 17.4 17.4 8.7 8.7 4.3 4.3
Sinus bradycardia 8.7 4.3 4.3 NAD NAD NAD 4.3 4.3
PVC 4.3 4.3 4.3 NAD NAD NAD NAD NAD
PAC NAD NAD NAD NAD 4.3 4.3 4.3 NAD
QRS widening 8.7 8.7 8.7 8.7 4.3 NAD 4.3 NAD
ST. elevation 8.7 4.3 8.7 NAD 8.7 NAD 13.0 NAD
A.F. NAD NAD 4.3 NAD NAD NAD 4.3 NAD
V.T NAD NAD NAD NAD 13.0 21.7 4.3 NAD
V.F. NAD NAD NAD NAD 4.3 4.3 NAD 4.3
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damage and fluid loss (Mehrpour et al. 2009, 2012, 2014a; 
Mehrpour and Singh 2010).
So far, supportive therapy is the main treatment for 
such patients since there is no specific antidote to stop 
AlP poisoning (Mostafazadeh and Farzaneh 2012).
Treatment of cardiogenic shock as one of the main 
causes of death in AlP poisoning may reduce the relevant 
mortality (Mehrpour et  al. 2011, 2012, 2014b). Intra-
aortic Balloon Pump (IABP) (Mehrpour et  al. 2014b), 
glucagon (Oghabian and Mehrpour 2016), and digoxin 
(Mehrpour et  al. 2011) are used to manage cardiogenic 
shock in some treatments. IABP has been shown to be 
another excellent treatment for AlP poisoning by previ-
ous studies. Moreover, in severe cases of AlP poison-
ing, IABP addition to the treatment protocol has been 
strongly recommended by some researchers besides 
using Extracorporeal Membrane Oxygenation (ECMO) 
(Hassanian-Moghaddam et al. 2016).
Acidosis can be reversed through improved uptake 
of myocyte carbohydrate (Hassanian-Moghaddam and 
Zamani 2016). Also, the use of hyperinsulinemia/eug-
lycemia (HIE) as another useful treatment improves 
inotropy and peripheral vascular resistance (Hassanian-
Moghaddam and Zamani 2016).
Fig. 1 Estimated marginal means in two groups over time
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Furthermore, coconut oil, which is believed to inhibit 
phosphine gas release from AlP due to the physicochemi-
cal properties of aluminium phosphide and its non-mis-
cibility with fat (Shadnia et al. 2005) has been suggested 
for gastric lavage in acute AlP poisoning by some 
researchers (Shadnia et al. 2005).
Oxidative stress is one of the main mechanisms of AlP 
to induce toxicity (Mehrpour et al. 2012, 2014a). Vitamins 
C and E and N-acetylcysteine (Oghabian and Mehrpour 
2016) as antioxidant agents have been shown by the pre-
vious studies to have significant benefits in AlP poisoning 
management. Recently, via a combination of the men-
tioned antioxidant agents and intravenous glucagon and 
digoxin, AlP poisoning has been successfully reported 
to be treated by Oghabian and Mehrpour (2016). Mean-
while, that oxidative stress is believed by Abdollahi et al. 
(2004) to be one of the main mechanisms of AlP toxicity, 
which is somewhat similar to those of organophosphate 
(OP) compounds (Abdollahi et al. 2004).
Also, glutathione as a main antioxidant defense is 
reduced by AlP. Actually, changes in glucose metabolism 
were associated with AlP and OP that cause a toxic stress 
in a similar way (Rahimi and Abdollahi 2007; Nath et al. 
2011). Antioxidant agents seem to usefully reduce the 
toxicity. Cellular glutathione and magnesium have been 
shown to be replenished in rats (Hsu et  al. 2000, 2002) 
and humans (Chugh et al. 1997) with the help of N-ace-
tylcysteine, which has antioxidant properties through dif-
ferent studies. Myocardial oxidative injury in rats exposed 
to AlP has been shown to be reduced by N-acetylcysteine, 
while increasing their survival times (Bogle et al. 2006).
In this study, N-acetylcysteine was examined for reduc-
ing oxidative stress and AlP causing cardiotoxicity. In 
these patients, cardiogenic shock and cardiotoxicity are 
the most important causes of mortality. Various types of 
cardiac dysrhythmia, such as VT (17.4%), sinus tachycar-
dia (10.87%), VF (8.7%), ST elevation (8.7%), widening of 
QRS (8.7%), sinus bradycardia (6.5%), PAC (6.5%), PVC 
(2.2%), and AF (2.2%) were discovered in this research. 
No significant difference was found between the groups 
though the case group was associated with a lower rate 
of dysrhythmia. In cases of AlP poisoning various types 
of cardiac events or dysrhythmia may be happened such 
as sinus tachycardia. VF, VT, ST elevation, widening of 
QRS, sinus bradycardia, PAC, PVC, and AF. Of them VF 
and VT seems to be terminal cardiac dysrhythmia before 
death (Mehrpour et al. 2012).
In the previous studies, ECG changes including ST-T 
changes, AV conduction disturbances, bundle branch 
blocks, supraventricular and ventricular tachycardia, and 
atrial fibrillation have been precisely investigated (Jain 
Sm et al. 1985; Chugh et al. 1989, 1991; Soltaninejad et al. 
2012).
In their study, Chugh et al. found 50% of ECG abnor-
mality incidence in AlP poisoning cases. Nearly, equal 
frequencies of ischemic pattern, conduction distur-
bances, and dysrhythmias were discovered by them. In 
their study, varied electrical alternates, sino-atrial blocks, 
and early repolarization and bradycardia-tachycardia 
syndromes were observed, while no ECG abnormality 
effects on mortality were found (Jain Sm et al. 1985). 45% 
of dysrhythmia cases were discovered by Soltaninejad 
et al. 20, 35, 45, and 45% of the intervals, prolonged QTc, 
Bundle Branch Block (BBB), and ST-segment elevation 
were seen, respectively (Soltaninejad et al. 2012).
Myocardial damage caused by AlP poisoning was also 
confirmed by biochemical biomarkers of cardiac mus-
cle injury, such as CPK, CK-MB, and Troponin-T (Sol-
taninejad et al. 2012). Myocardial damage can be traced 
by the many folds of CPK-MB and LDH elevations in AlP 
poisoning (Shah et  al. 2009; Anand et  al. 2012) though 
elevation of CPK levels without any changes in CPK-MB 
fraction was reported by Duenas et  al. (1999). Contrary 
to our finding, CPK levels and CPK/CPK-MB ratio were 
not found to be reliable cardiac injury markers in AlP 
poisoning by Soltaninejad et al. (2012). However, normal 
CPK levels at hospital admission were seen in another 
case report by Nayyar and Nair (2009). Though contro-
versial in some AlP poisoning case reports, cardiac mus-
cle injury has been clinically and laboratorially indicated 
by the changes in CPK and CK-MB levels. In some case 
reports, these markers led to normal serum levels after 
AlP poisoning (Bogle et al. 2006; Nayyar and Nair 2009). 
Nevertheless, myocardial injury caused by a rise in their 
levels was indicated in other reports (Akkaoui et  al. 
2007; Kaushik et al. 2007; Shah et al. 2009). Despite ECG 
changes in acute AlP poisoning, inconsistent reports of 
normal and abnormal CPK-MB levels are found (Kau-
shik et al. 2007; Soltaninejad et al. 2009). In addition, in 
a review article by Karami & Mohajeri, it was concluded 
that the normal levels of these enzymes cannot disprove 
cardiotoxicity though their elevated levels can corrobo-
rate myocardial damage (Karami-Mohajeri et al. 2013).
For the first time, CPK and CK-MB repeated measure-
ments were used in this study. Also, the four cardiac indi-
ces of CPK, CK-MB, SBP, and heart rate were evaluated 
and compared in the case and control groups. Myocar-
dial damage during AlP poisoning was confirmed by CPK 
and CK-MB enhancements in both groups with the pas-
sage of time. However, lower rates of CPK and CK-MB, 
especially after 12 and 18  h, respectively, and bradycar-
dia deceleration in SBP over time were revealed in the 
case group receiving NAC. AlP poisoning treatment with 
antioxidants, especially NAC in our study was the same 
result obtained by other investigations (Duenas et  al. 
1999). Meanwhile, significantly lower rates of intubation, 
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ventilation, and mortality and shorter duration of hospi-
talization were found in AlP-poisoned patients treated 
with NAC compared to the controls in the previous study 
(Tehrani et al. 2013).
Some limitations in our study included exclusion of 
patients who died within the first 24 h of admission and 
inability to analyze the different variables between the 
two groups based on alive or dead patients due to the 
small number of dead patients in both groups. None-
theless, reduced rate of mortality in AlP patients was 
clearly found to be resulted from NAC effect on some 
cardiac variables, such as heart rate and SBP in this 
study.
Conclusion
Our patients could be managed by the positive role of 
NAC as the biochemical index of cardiotoxicity was 
found to elevate in both the case and control groups. 
Therefore, for the management protocol optimization, 
NAC evaluation should be done in further cases.
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